P3H4

Across TCGA pan-cancer cohorts, P3H4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated P3H4 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher P3H4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated P3H4 expression acts as an unfavorable survival marker.

CESC, PRAD, and COAD are the cancer types where P3H4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.096	0.546	.009	12	view →
PRAD	DFS	Median	All	0.068	0.935	<.001	6	view →
COAD	DFS	Median	All	0.202	0.699	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

P3H4–CESC (DFS)

Open the CESC breakdown →